Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus

Friday, September 20, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. has announced the launch of OsteoVive Plus, a viable bone matrix product. This addition enhances their existing product portfolio aimed at surgical solutions for spinal disorders. The launch reflects the company's commitment to innovation in the medical technology sector.
Price reaction · baseline $0.568 (2024-09-19 close) · hit pre-market · 1 other XTNT headline(s) in the window, move may be shared
day 0 close
+23.7%
day 1 · peak
+30.3%
day 3
+19.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of new product, OsteoVive Plus.
  • Expansion of Xtant Medical's product portfolio.
  • Focus on surgical solutions for spinal disorders.

Full Press Release Details

BELGRADE, MT / ACCESSWIRE / September 18, 2024 /) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has launched a new addition to its robust product portfolio, OsteoVive

Frequently Asked Questions

What is OsteoVive Plus?

OsteoVive Plus is a new viable bone matrix product launched by Xtant Medical.

What company launched OsteoVive Plus?

Xtant Medical Holdings, Inc. launched OsteoVive Plus.

What is the focus of Xtant Medical?

Xtant Medical focuses on surgical solutions for the treatment of spinal disorders.

When was OsteoVive Plus launched?

OsteoVive Plus was announced on September 18, 2024.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical OsteoVive Plus spinal disorders medical technology surgical solutions
Last updated: Sep 20, 2024

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk